Why the study?
Does Carbonic anhydrase II (CAII) promote cardiomyocyte hypertrophy in preclinical models?
Population
Neonatal rat ventricular myocytes (NRVMs) and CAII-deficient (Car2) mice
Comparison
Over-expression of wild-type CAII or… vs Endogenous CAII / wild-type controls
Design
Preclinical
Authors
Loading...
CAII promotes hypertrophy in rodent cardiomyocytes; hypothesis-generating for therapeutic targeting in human remodeling.
Does Carbonic anhydrase II (CAII) promote cardiomyocyte hypertrophy in preclinical models?
Cytosolic Carbonic anhydrase II (CAII) plays a crucial role in promoting cardiomyocyte hypertrophy, highlighting its potential as a therapeutic target in pathological cardiac remodeling.
Brown et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: